May 11, 2009 –
|
RELATED TICKERS: MYGN
, GHDX
, SQNM
I’ve abandoned my attempts to pick GOOD baby biotechs over the last few months as the broad market has rebounded counterintuitively, and I believe that the vast majority of stocks are overpriced for short term performance. While there are still good bets for the long term, I refuse to take an immediate haircut in real life or in CAPS by getting suckered into what I believe is a bear rally of ridiculous proportions. However, two companies in one of my favorite biotech sectors have recently suffered vigorous thrashings which I believe position them to be successful investments in the short-term as well as the long-term. That sector is molecular diagnostics, in which the marketed products are genetic assays rather than pharmaceuticals. The beauty of these products is that they do not need to meet the rigorous safety and efficacy standards of pharmaceuticals and are therefore much more likely to attain FDA approval without the hundreds of millions in trial expenses. The companies that specialize in molecular diagnostics are using cutting edge technology to help physicians optimize the use of approved treatments, which renders those treatments much more effective and valuable. [more]
March 31, 2009 –
To stick my head out of the foxhole? This is a follow-up to yesterday’s post. [more]
March 30, 2009 –
Did someone already write this post? Hopefully not. I’m still a little young to be the guy who tells you the story that you just told him yesterday. This is an attempt to coalesce in a thread some thoughts that highly contributing members have had about improvements we would like to see on CAPS. TMFJake, I’m aware you are on the case and I appreciate your efforts. But after the last “upgrade” I think it would be best for our preferences to be on the record before any changes are made. For those of like mind, please keep comments on point so that we can maintain this thread and eventually arrive at a mutually satisfactory slate of prospective improvements to present to TMF. As attention spans are short, I’m going to make the suggestions first and then rant afterwards. [more]
February 23, 2009 –
I'm not sure it's good to be a Fool these days, so I'll refer to myself as an Idiot when asking this question I'm sure has been asked and answered many times. [more]
February 17, 2009 –
|
RELATED TICKERS: PGNX
, LJPC
The central purpose of my concentration on the small-cap biotech sector is to disprove the hypothesis that the market cannot be beaten, i.e. that at any given moment the price of a stock closely reflects the weighted average of all possible outcomes for the company given all information publicly available. Needless to say, to accept this efficient market hypothesis is to render retail investing useless, as the laws of probability dictate an eventual zero sum game minus the costs of trading. [more]
Terms & Conditions
RSS Headlines
Fool UK